Mumbai – 400 001

AarƟ Drugs posted revenue of Rs. 652.9 crore in Q2 FY26, growing 9% year-on-year, with EBITDA of Rs. 84.4 crore, up 23%, with margin at 12.9%.

For H1 FY26, revenue was Rs. 1,243.7 crore, up 8% year-on-year, with EBITDA of Rs. 158.8 crore, up 18% with margin at 12.8%.

These trade dynamics have also affected the cost structure and availability of critical APIs, challenging manufacturers globally.

Gross profit margin improvement is primarily attributed to the normalization of input cost.

The capex incurred during Q2 FY26 was Rs. ~45.6 crore.

Our salicylic acid operations at Tarapur are stabilizing well with near-term output of around 300 tonnes per month and targeting 500 tonnes per month for Q4 FY26.